The new $5.3 billion deal with the Swiss pharma giant gives Zealand a significant partner to advance its amylin analog obesity shot and create a new combination product.

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand Pharma’s obesity drug candidate.

ZURICH, March 12 (Reuters) - Roche (ROG.S), opens new tab has acquired rights to an obesity therapy by Denmark's Zealand Pharma (ZELA.CO), opens new tab in a collaboration deal worth up to $5.3 ...

Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor agonists but without the side effects associated with GLP-1 drugs.

Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this deal is a win-win for RHHBY & ZLDPF.

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss drugmaker seeks to boost its prospects in the booming ...

Roche is expanding its scope to a promising but competitive new obesity target, committing $1.65 billion up front to partner on a clinical-stage Zealand Pharma molecule with the potential to be a ...

ZURICH (Reuters) -Roche has acquired rights to an obesity therapy by Denmark’s Zealand Pharma (NASDAQ:ZEAL) in a collaboration deal worth up to $5.3 billion, as the Swiss drugmaker seeks to ...

For more on Immunovant’s new data, go here; for more on Sarepta’s gene therapy, go here; to learn more about Zealand’s deal ...

Roche and Zealand Pharma have formed a potential $5.3 billion collaboration to bring amylin analog petrelintide to market as an obesity treatment, both on its own and in combination with Roche's ...